Evidence map›Paper›PMID 41012707›Full record

ArticleViruses2025

Ruvidar

Kevin M Coombs, Roger DuMoulin-White, Arkady Mandel

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kevin M CoombsDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.ORCID 0000-0001-7667-8430
Roger DuMoulin-WhiteTheralase® Technologies Inc., 41 Hollinger Road, Toronto, ON M4B 3G4, Canada.ORCID 0000-0002-6745-4379
Arkady MandelTheralase® Technologies Inc., 41 Hollinger Road, Toronto, ON M4B 3G4, Canada.

Funding

This research was supported by unrestricted funding provided by Theralase® Technologies, Inc. to K.M.C no
6 · The paper itself

Abstract

Infectious agents account for millions of deaths every year. The Herpes Simplex Viruses (HSVs) are large double-stranded DNA viruses that infect more than 90% of the human population and can establish life-long latency in human hosts. Currently, effective FDA approved anti-herpetic drugs include acyclovir and later-generation derivatives (valacyclovir and famciclovir), which inhibit viral DNA synthesis. In previous work, we demonstrated that the small molecule Ruvidar

Indexed as

Antiviral AgentsHerpesvirus 1, HumanAcyclovirAnimalsChlorocebus aethiopsDrug SynergismHerpes SimplexHumansMetforminVero CellsVirus ReplicationAcyclovirAntiviral AgentsMetforminacyclovirantiviralslipid envelopemetforminphotodynamic therapyRutherrin®Ruvidar®TLD-1433

Identifiers

PMID41012707
PMCPMC12474290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.